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The insulin-like growth factor-1 receptor (IGF-1R) signaling pathway is critical for both normal mammary gland development and
malignant transformation. It has been reported that the IGF-1 stimulates breast cancer cell proliferation and is upregulated in
tumorswithBRCA1/2mutations.WereportherethatIGF-1isnegativelyregulatedbyBRCA1atthetranscriptionallevelinhuman
breast cancer cells. BRCA1 knockdown (BRCA1-KD) induces the expression of IGF-1 mRNA in MCF7 cells in an estrogen
receptor a (ERa)-dependent manner. We found that both BRCA1 and ERa bind to the endogenous IGF-1 promoter region
containing an estrogen-responsive element-like (EREL) site. BRCA1-KD does not signiﬁcantly affect ERa binding on the IGF-1
promoter. Reporter analysis demonstrates that BRCA1 could regulate IGF-1 transcripts via this EREL site. In addition, enzyme-
linked immunosorbent assay revealed that de-repression of IGF-1 transcription by BRCA1-KD increases the level
of extracellular IGF-1 protein, and secreted IGF-1 seems to increase the phospho-IGF-1Rb and activate its downstream
signalingpathway.BlockingtheIGF-1/IGF-1R/phosphoinositide3-kinase(PI3K)/AKTpathwayeitherbyaneutralizingantibodyor
by small-molecule inhibitors preferentially reduces the proliferation of BRCA1-KD cells. Furthermore, the IGF-1-EREL-Luc
reporter assay demonstrates that various inhibitors, which can inhibit the IGF-1R pathway, can suppress this reporter activity.
These ﬁndings suggest that BRCA1 defectiveness keeps turning on IGF-1/PI3K/AKT signaling, which signiﬁcantly contributes to
increase cell survival and proliferation.
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The insulin-like growth factors (IGFs), both IGF-1 and IGF-2,
arepeptidehormonesthathaveimportantrolesinmammalian
growth and development.
1 IGF-1 is structurally similar to
insulin, but has a much higher growth-promoting activity
(http://www.uniprot.org/). IGF-1 binds to the IGF-1 receptor
(IGF-1R) homodimer or the IGF-1R/insulin receptor hetero-
dimer and provokes intracellular signaling cascades.
2,3
Similar to insulin, IGF-1 not only acts as a growth factor at
the cellular level but also functions as a hormone regulating
growth and energy metabolism at the whole-organism level.
3
IGF-1R is activated by extracellular IGF-1 and is autopho-
sphorylated at multiple tyrosine residues in its kinase
domain.
4 Activation of IGF-1R induces the diverse signaling
pathways such as the phosphoinositide 3-kinase (PI3K)/AKT
and the mitogen-activated protein kinase (MAPK) pathways
that are important to cell proliferation, transformation and
survival.
3–5IGF-1Riscommonlyexpressedinhumancancers
including breast cancers.
3–5 Phospho-IGF-1R is detected by
immunostaining in about half of breast tumors irrespective of
their subtypes, which is associated with poor outcome.
5
The transcriptional regulation of human IGF-1 is not well
understood yet. Although mouse Igf-1 is regulated by
estrogen via direct binding of estrogen receptor a (ERa)t o
estrogen-responsive elements (EREs) in its promoter,
6 there
is no known consensus ERE in the human IGF-1 promoter.
7,8
The chromatin immunoprecipitation (ChIP) analysis,
however, demonstrates that ERa binds to human IGF-1
promoter region,
8 and human IGF-1 mRNA expression is
activatedbyestrogeninhumanovarianandbreastcancercell
lines.
7,8 Furthermore, intratumoral IGF-1 protein is elevated in
breast cancer patients carrying breast cancer susceptibility
gene 1/2 (BRCA1/2) mutations.
9 Although it has been shown
that siRNA-based BRCA1 knockdown (BRCA1-KD) induces
intracellular IGF-1 levels in primary human mammary gland
cells,
9 the underlying molecular mechanism in human normal
or tumor cells still remains to be determined.
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www.nature.com/cddisGermline mutations in the BRCA1 gene drastically increase
the risk of breast and ovarian cancers in the individuals who
carry them.
10,11 In addition, the level of BRCA1 protein is also
often decreased or absent in sporadic breast and ovarian
cancers.
12,13Asatumorsuppressor,BRCA1isinvolvedinthe
regulation of cell-cycle progression, DNA damage and repair
and maintenance of genomic integrity.
14 Although BRCA1 is
not a sequence-speciﬁc DNA-binding protein, it functions as a
transcriptionalmodulatorsviaphysicalinteractionwithvarious
transcription factors (such as ERa, p53, STAT1, c-Myc, and
ZBRK1) and regulates their target gene expression.
15 ERa,
a member of the steroid hormone receptor superfamily, is
activated by estrogen and has important roles in normal
development and tumorigenesis of the breast.
2 BRCA1
interacts with ERa and represses the ERa-mediated
transcriptional activity either in an estradiol (E2)-dependent
16
or -independent manner.
17
In this paper, we report that BRCA1 represses IGF-1
transcription in an ERa-dependent manner. Our study also
suggests that de-repression of IGF-1 transcription by BRCA1
knockdown may induce a positive-feedback loop in an
autocrine manner and result in further activation of IGF-1
transcripts through the IGF-1R/PI3K/AKT pathway.
Results
Expression of IGF-1 is negatively regulated by BRCA1.
In order to identify genes regulated by BRCA1, we performed
microarray analysis using RNA samples from MCF7 cells
transfected with siRNA (control versus BRCA1). One of
the genes that were signiﬁcantly upregulated by BRCA1-KD
was IGF-1 (data not shown). To further conﬁrm this, we
performed quantitative real-time PCR (qRT-PCR) analysis
and found that BRCA1-KD signiﬁcantly increased the level of
IGF-1 mRNA in the human breast cancer cell line, MCF7 and
prostate cancer cell line, DU145 – both of which are
ERa-positive (Figures 1a and b). However, BRCA1-KD did
not signiﬁcantly change the expression of IGF-2, IGF-1R,
and IRS-1 in MCF7 cells (Supplementary Figure S1).
Interestingly, BRCA1-KD did not affect IGF-1 gene expres-
sion in two ER-negative breast cancer cell lines, MCF10A
and MDA-MB-231 (data not shown), suggesting the potential
involvement of ERa in the regulation of IGF-1 by BRCA1.
In addition, overexpression of wild-type BRCA1 signiﬁcantly
decreased the level of IGF-1 mRNA in MCF7 cells
(Figure 1c).
To further evaluate estradiol (E2) dependency, we
performed qRT-PCR analysis with MCF7 cells treated with
siRNA (control versus BRCA1) under either normal growth or
E2-stimulated conditions in the absence or presence of an
antiestrogen, ICI182780. Under normal growth conditions,
BRCA1-KD-induced IGF-1 mRNA expression was signiﬁ-
cantly but not completely reduced by ICI182780 (Figure 1d),
whereas treatment of ICI182780 nearly completely abolished
BRCA1-KD-induced IGF-1 mRNA expression in E2-stimu-
lated MCF7 cells (Figure 1e). These results suggest that the
induction of IGF-1 mRNA expression is estrogen-dependent
in BRCA1-KD MCF7 cells under E2-stimulated conditions.
ICI182780 also reduced IGF-1 mRNA expression levels
of control-siRNA-treated MCF7 cells in both normal growth
and E2-stimulated conditions. Under these conditions,
administration of ICI182780 reduced the BRCA1 mRNA
expression level in control-siRNA-treated MCF7 cells in both
conditions (Figures 1d and e). It has been reported that
ICI182780 inhibited E2-induced BRCA1 mRNA induction
in ER-positive cells.
18
BRCA1 represses the human IGF-1 promoter through
an ERE-like site. Although it is reported that human IGF-1
gene expression is regulated by estrogen in human ovarian
and breast cancer cell lines, no known consensus ERE site
has been reported in human IGF-1 promoter.
7,8 Interestingly,
the chicken promoter contains an ERE-like (EREL) site, but a
reporter construct containing mutations of this EREL site is
still activated by estrogen in human hepatocellular carcinoma
HepG2 cells.
19 Sasaki et al.,
8 however, subsequently
demonstrated by ChIP analysis that ERa binds to the human
IGF-1 promoter region ( 111 to  312) containing this
EREL site in human ovarian cancer cell lines and described
that this region contains an activator protein 1 (AP1) site.
To identify potential sequence elements that involve
E2-dependent regulation of the human IGF-1 promoter, we
performed sequence analysis of this IGF-1 promoter region.
Sequence analysis of this region failed to identify consensus
ERE (GGTCAnnnTGACC) or AP1 (T
T/GAGTCAG) site.
Instead, an EREL site, as previously identiﬁed in the chicken
IGF-1 promoter,
19 is highly conserved in human, mouse, and
chicken IGF-1 promoters (Figure 2a).
To determine whether BRCA1 and/or ERa binds to
this region, we further performed ChIP analysis under
E2-stimulated conditions. The ChIP assay revealed the occu-
pation of both ERa and BRCA1 on the IGF-1 promoter region
containing this EREL site in MCF7 cells (Figures 2b and c).
BRCA1-KD abolished the interaction of BRCA1 with the
human IGF-1 promoter in an E2-independent manner
(Figures 2b and c). BRCA1-KD itself did not signiﬁcantly
affectERabindingtothehumanIGF-1promoterinMCF7cells
under estrogen-deprived conditions (Figure 2c, lower). On the
contrary, stimulation by E2 markedly increased ERa binding
on the IGF-1 promoter in both control and BRCA1-KD MCF7
cells (Figures 2b and c). As expected, the antiestrogen,
ICI182780, reduced E2-induced ERa binding to the IGF-1
promoter.
Next, we prepared three different reporter constructs
of the human IGF-1 promoter: (1) IGF-1-1kb-Luc, (2) IGF-1-
EREL-Luc construct contained one copy of wild-type
EREL sequence, and (3) IGF-1-EREL-Luc construct con-
tained the mutant EREL sequence. In estrogen-deprived
MCF7 cells, E2 administration induced reporter activities from
both IGF-1-1kb-Luc (Supplementary Figure S2a) and wild-
type IGF-1-EREL-Luc (Figure 3a) in a dose-dependent
manner. Mutation of the EREL site completely abolished
E2-induced expression of the reporter gene (Figure 3a).
Under these conditions, we found that 10nM of E2 induced
approximately ﬁve-fold increase in the reporter activity from
a control reporter containing a consensus ERE element
(Figure 3b). In addition, transient overexpression of BRCA1
suppressed the E2-induced wild-type IGF-1-ELEL-Luc repor-
ter activity in a dose-independent manner, whereas little or no
effect was observed in the absence of E2 (Figure 3c).
BRCA1 regulates IGF-1 signaling
HJ Kang et al
2
Cell Death and DiseaseConsistently, BRCA1-KD increased the reporter activity from
wild-typeIGF-1-EREL-Lucin MCF7cellsunderE2-stimulated
conditions (Figure 3d). Interestingly, BRCA1-KD could induce
IGF-1-EREL-Luc reporter activity even in the absence of
E2 stimulation (Figure 3d), whereas mutation of the EREL
site completely abolished BRCA1-KD-dependent induction of
reporter activity. BRCA1-KD also induced activation of IGF-1-
1kb-Luc (Supplementary Figure S2b), wild-type IGF-1-EREL-
Luc, and consensus ERE-Luc (Supplementary Figure S2c) in
MCF7 cells under normal growth conditions.
Carboxy-terminal domain of BRCA1 has important roles
in the regulation of human IGF-1 promoter. A previous
study reports that the amino-terminus of BRCA1 interacts
with ERa, whereas the carboxy-terminus of BRCA1 functions
as a transcriptional repression domain using consensus
ERE-Luc promoter reporter gene.
20 To determine the effects
of BRCA1 tumor-associated mutations on transcriptional
regulation by the EREL site of the human IGF-1 promoter,
we performed reporter gene assays with wild-type IGF-1-
EREL-Luc in the presence of various BRCA1 mutants
and wild-type BRCA1 (Figure 4). The wild-type BRCA1
suppressed this reporter activity in the presence of E2
(38.4±2.0%), compared with pCDNA3-transfected control
(100±3.7%). A tumor-associated BRCA1 mutant, carrying
the T300G mutation in the amino-terminal RING domain,
suppressed the reporter activity to the similar levels as wild-
type BRCA1 (30.7±3.1%). However, one carboxy-terminal
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Figure 1 Negativeregulationof IGF-1mRNA expression by BRCA1.(a and b) Total RNAsextracted fromcells transfected with 100nM of siRNA (controlversus BRCA1)
for 72h were used for qRT-PCR assay to quantify the level of BRCA1 and IGF-1 transcripts in MCF7 and DU145 cells. (c) Total RNAs isolated from the cells transfected with
1mg of DNA expression vector (control versus BRCA1) for 24h were subjected to qRT-PCR assay analysis as in (a and b). (d) Total RNAs were extracted from MCF7 cells
transfected with 100nM of siRNA (control versus BRCA1) for 48h followed by 24h treatment of ICI182780 under normal growth conditions and used for qRT-PCR assay to
monitorthelevels ofBRCA1and IGF-1transcripts. (e)MCF7 cellsculturedwith phenol-red-freeDMEMsupplementedwith charcoal-stripped FBS(CS-FBS)weretransfected
with 100nM siRNA (control versus BRCA1) for 3 days. Transfected cells were further treated with 10mM ICI182780 for 24h and stimulated by 10nM of E2
in phenol-red-free DMEM containing CS-FBS. After extraction of total RNAs, qRT-PCR assays were performed as in (d). Representative data from two independent
experiments performed in triplicate are shown as mean±S.E.M. *Po0.05; **Po0.01 and ***Po0.001
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Cell Death and Diseasetumor mutant, 5382insC (Q1756term), failed to suppress
wild-type IGF-1-EREL-Luc reporter activity (82.1±7.5%).
Similarly, another carboxy-terminal BRCA1 mutant,
5677insA (Y1853term), also showed reduced suppression
of reporter activity (74.0±2.4%). Because all three BRCA1
mutants are known to physically interact with ERa,
20 these
results indicate that the carboxyl-terminal domain of BRCA1
is important in repressing IGF-1-EREL-Luc reporter activity.
In addition, a carboxy-terminal deletion mutant (BamHI
(NT); aa 1–1313) did not repress reporter activity at all
(107.0±4.9%). These results suggest that the intact
carboxy-terminal repression domain has important functions
in suppressing E2-induced IGF-1 reporter activity. Interest-
ingly, the carboxy-terminal domain of BRCA1 (BamHI
(CT); aa 1314–1863), which lacks the ERa-interacting
domain, still has partial repression activity on the wild-type
IGF-1-EREL-Luc reporter (61.9±3.5%).
Secreted IGF-1 autocrinely activates the IGF-1R pathway
in BRCA1-KD MCF7 cells. To determine the effect of
BRCA1-KD on IGF-1 secretion, we measured IGF-1 protein
in the culture medium by enzyme-linked immunosorbent
assay (ELISA). The culture media harvested from cells
treated with siRNA (control versus BRCA1) for 72h were
subjected to ELISA analysis. The amount of the secreted
IGF-1 protein was signiﬁcantly increased in BRCA1-KD
MCF7 cells and administration of an IGF-1 neutralizing
antibody completely reduced the secreted IGF-1 protein in
these cells (Figure 5a). In addition, BRCA1-KD also induced
IGF-1 secretion in another ERa-positive cell line, DU145, but
not in ERa-negative MCF10A cells (Figure 5b).
To further evaluate the effect of IGF-1 induction by
BRCA1-KD, we performed western blot analysis. BRCA1–KD
induced phospho-IGF-1Rb (Y1135), while there were barely
detectable levels of phospho-IGF-1Rb in control-siRNA-treated
cells (Figure 6a). Phosphorylation of AKT, a downstream
effector of the IGF-1R pathway, at S473 was also increased
by BRCA1-KD. Increase in phospho-IGF-1Rbwas also observed
in the BRCA1-KD DU145 cells (Figure 6b), whereas no signiﬁ-
cant increase of phospho-IGF-1Rb was observed in BRCA1-KD
MCF10A cells (Figure 6b). Consistently, overexpression of
wild-typeBRCA1inMCF7cellsfurtherdecreasedbasallevels
of phospho-IGF-1Rb (Supplementary Figure S3a).
The speciﬁcity of increased IGF-1Rb phosphorylation was
further conﬁrmed by either a neutralizing antibody or a small-
molecule inhibitor. Administration of a neutralizing IGF-1
antibody abolished BRCA1-KD-induced phospho-IGF-1Rb
(Y1135) and phospho-AKT (S473) in a dose-dependent
manner (Figure 6a). In addition, an IGF-1R tyrosine kinase
inhibitor, BMS-536924, (Supplementary Table S1) also
inhibited phospho-IGF-1Rb (Y1135), phospho-ATK (S473),
and phospho-GSK3b (S9) in a dose-dependent manner in
BRCA1-KD MCF7 cells (Figure 6c). Treatment of BMS-
536924 reduced levels of BRCA1 in control-siRNA-trans-
fected MCF7 cells in a dose-dependent manner (Figure 6c).
Moreover, treatment with ICI182780 blocked BRCA1-KD-
inducedphosphorylationofIGF-1Rb (Y1135)andAKT(S473)
in MCF7 cells cultured in either normal growth conditions
(Supplementary Figure S3b) or E2-stimulated conditions
(Supplementary Figure 3c). All these results support that the
loss of BRCA1 function can autocrinely activate the IGF-1R
pathway in an E2-dependent manner.
Knockdown of BRCA1 sensitizes MCF7 and ZR-75-1
cells to IGF-1R inhibitors. Next, we performed 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays
to determine the cytotoxic effects of small-molecule IGF-1R
inhibitors, BMS-536924 and GSK1904529A, in BRCA1-KD
ERa-positive breast cancer cell lines. MCF7 cells pretreated
with siRNA (control versus BRCA1) were incubated with increas-
ing amounts of IGF-1R inhibitors for 48h, and cell viability
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Figure 2 Binding of endogenous BRCA1 and ERa to the promoter regions of
human IGF-1. (a) Schematic diagram of the human IGF-1 promoter showing the
location and sequence of the ERE-like (EREL) sequence. (b) Cells pretreated with
siRNA (control versus BRCA1) were used for ChIP assay. Endogenous promoter
regions associated with BRCA1 and/or ERa were immunoprecipitated with anti-
BRCA1oranti-ERaantibody,respectively.TherelativeamountsofIGF-1promoter-
speciﬁc DNA containing the EREL site in immunoprecipitated complexes were then
determined by semiquantitative PCR as described in Materials and Methods.
The non-ERE region in IGF-1 promoter was used as negative control. (c) Using
the same DNA samples obtained in (b) qRT-PCR was performed. (b and c)
Representative data from two independent experiments performed in duplicate are
shown as mean±S.E.M. ***Po0.001
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Cell Death and Diseasewas measured by MTT assay. As results, BRCA1-KD
cells showed increased sensitivity to both inhibitors in a
dose-dependent manner (Figure 7a). Two other IGF-1R
inhibitors, OSI-906 and AG 1024 (Supplementary Table S1),
also preferentially inhibited proliferation of BRCA1-KD MCF7
cells (Figure 7b). As expected, transient overexpression of
wild-type BRCA1 conveyed resistance of MCF7 cells
to BMS-536924, OSI-906, and AG 1024 (Figure 7c). Results
were conﬁrmed in another ERa-positive breast cancer cell
line, ZR-75-1, in which BRCA1-KD conferred increased
sensitivity to IGF-1R inhibitors (Figure 7d).
Pharmacological inhibition of the IGF-1R/PI3K/AKT
pathway reduces EREL-mediated transcription in
BRCA1-KD cells. Given that IGF-1 induces transcriptional
activation mediated by ERE,
21,22 we hypothesized that
BRCA1-KD-induced IGF-1R/PI3K/AKT signaling can partici-
pate in the activation of IGF-1 transcription through the
EREL site. Both the neutralizing IGF-1 antibody and an
IGF-1R inhibitor (OSI-906) signiﬁcantly suppressed wild-type
IGF-1-EREL-Luc reporter activity in BRCA1-KD MCF7 cells
in a dose-dependent manner (Figure 8a). Additionally, the
inhibitor of AKT translocation (Perifosine) or PI3K kinase
(BEZ235) also signiﬁcantly suppressed IGF-1 reporter
activity induced by BRCA1-KD in MCF7 cells (Figure 8a).
As expected, treatment of ICI182790 signiﬁcantly suppressed
BRCA1-KD-induced IGF-1-EREL-Luc reporter activity. Several
studies show that activated AKT can contribute to ERa
phosphorylation, which may be important for its transcrip-
tional regulation activity.
2 Because IGF-1-induced activation
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Figure 3 Regulation of IGF-1-EREL-Luc reporter activity by BRCA1 in the presence or absence of estradiol (E2). (a) MCF7 cells transfected with IGF-1-EREL-Luc
(wild type versus mutant) or (b) consensus ERE-Luc for 24h were further treated with or without E2 under estrogen-deprived conditions. After 24h of treatment, cells were
harvested and luciferase activity was measured as described in Materials and Methods. (c) Effects of wild-type BRCA1 overexpression on the wild-type IGF-1-EREL-Luc
promoter reporter in the absence or presence of E2. Cells transfected with the wild-type IGF-1-EREL-Luc reporter and increasing amounts of BRCA1 expression vector
(pcDNA3-BRCA1) overnight were further incubated in the absence or presence of E2 under estrogen-deprived conditions. Then, cells were harvested to measure luciferase
activity.(d)EffectsofBRCA1-KDonthewild-typeIGF-1-EREL-Lucpromoterreporter.CellspretreatedwithsiRNA(controlversusBRCA1)for72hweretransfectedwithwild-
typeIGF-1-EREL-Luc for 24h under E2-stimulated conditionsand luciferase activity was measured. (a–d) Representative data from two independentexperiments performed
in triplicate are shown as mean±S.E.M. **Po0.01 and ***Po0.001
BRCA1 regulates IGF-1 signaling
HJ Kang et al
5
Cell Death and Diseaseof IGF-1R/PI3K/AKT signaling in BRCA1-KD cells may
continuously stimulate IGF-1 mRNA expression, we are
proposing that BRCA1-KD will keep turning on this pathway
in a ‘positive feedback’ manner (Figure 8b).
Discussion
There are several prior studies implicating BRCA1 in the
regulation of the IGF-1R pathway: (a) BRCA1 negatively
regulates IGF-1R transcription via the Sp1 transcription
factor;
23 (b) mRNA expression of several IGF-1R axis
members (including Igf-1, Irs-1, Igf-1r, and Igfbp2) increases
in the Brca1
D11/D11p53
þ/  mouse model;
24 and (c) intratu-
moral IGF-1 protein is upregulated in clinical samples of
breast cancer patients with BRCA1/2 mutations.
9 In compar-
ison, our study demonstrated that among IGF axis members
(IGF-1,IGF-2,IRS-1,andIGF-1R),IGF-1istheonlytranscript
that is regulated by BRCA1 in the MCF7 human breast cancer
cell line. In contrast to a previous ﬁnding in prostate cancer,
25
IGF-1R mRNA levels are not signiﬁcantly affected by
BRCA1-KD in MCF7 cells. Currently, these discrepancies
are not understood; differences in the induction of IGF axis
members by BRCA1 loss may be due to unidentiﬁed genetic
backgrounds of human versus mouse or breast versus
prostate cells.
Several lines of evidence support the cross-talk between
IGF-1R and ERa at different levels.
2,26 For example, IGF-1
induces transcriptional activation of ERa-target genes
21,22
and ERa can be activated by downstream factors of IGF-1R
such as MAPK or AKT.
2 In addition, ERa can activate IGF-1R
signaling not only by transcriptional activation but also by non-
genomic function. Membrane ERa can rapidly induce activa-
tion of several kinases including PI3K, ERK, and AKT.
2,26
Our data showed that transcriptional activation of the IGF-1
promoter, induced by BRCA1-KD, is downregulated not only
by IGF-1R inhibitors (either a neutralizing IGF-1 antibody or
an IGF-1R inhibitor) but also by inhibitors targeting PI3K or
AKT. Although the non-genomic function of ERa in the
absence of BRCA1 needs further investigation, our data
suggest that IGF-1 might be produced at higher levels in
breast cancers with a loss of BRCA1 function, which may
induce a ‘positive-feedback loop’ in activating IGF-1R/PI3K/
AKT/ERa signaling.
In our studies, when endogenous BRCA1 was knocked
down, proliferation seemed to rely more on the IGF-1R
pathway in MCF7 and ZR-75-1 cells. In fact, the phospho-
IGF-1R is detected in about 50% of breast cancer cells
irrespective of their subtypes and is associated with poor
survival rate.
5 Our results suggest that the IGF-1R signaling
pathway could be aberrantly overactivated in ERa-positive
breast cancer cells with defective BRCA1 (e.g. its low
expression level, point mutation, and so on). Therefore,
targeting the IGF-1R pathway in various ways could be a
potential option for prevention or therapy of BRCA1-defective
breast cancers. It is noteworthy that levels of BRCA1 are
reduced in sporadic breast cancers without BRCA1 muta-
tions.
12,13 Although most of the established human breast
cancercelllinescarryingBRCA1mutationsareERa-negative,
three-dimensionally cultured primary mammary epithelial
cells from BRCA1 mutation carriers have heterogeneous
ERa status: 32% ERa-negative, 44% mixed, 24% ERa-positive
versus 90% ERa-positive in controls.
27 Recently, ER-positive
-
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Cell Death and Diseasetumors have been identiﬁed in BRCA1 mutation carriers
that are Z50 years at the time of ﬁrst diagnosis of breast
cancer.
28 It has been also reported that approximately
10–36% of breast cancers that occur in BRCA1 mutation
carriers are ER-positive.
28
We demonstrated that an insertional mutation (5382insC)
and a carboxy-terminal deletion construct of BRCA1 are
defective in their ability to suppress wild-type IGF-1-EREL-
Luc reporter activity. The 5382insC mutation occurs in
approximately 0.4% of the Ashkenazi Jewish population
29
and is the most frequently observed BRCA1 mutation in non-
Jewish populations.
30 Like wild-type BRCA1, these BRCA1
mutants still physically interact with ERa by their amino-
terminal domains,
20 but their mutation/deletion in the car-
boxyl-terminal domain may abolish their suppressive function
on ERa-mediated transcriptional regulation.
We found that BRCA1 has little or no effect on E2-induced
binding of ERa to IGF-1 promoter (Figures 2b and c). This
resultimplicatesthatthebindingofligand-boundERatoIGF-1
promoter is independent of BRCA1 binding. Then, how does
BRCA1 regulate IGF-1 transcription? Previously, it is postu-
lated that the transcriptional repression of ERa by BRCA1
occursthroughestrogen-independentinteractionbetweenthe
amino-terminus of BRCA1 and the carboxy-terminal activa-
tion domain (AF-2) of ERa.
20 It was subsequently shown that
p300andcyclinD1maycompetewithBRCA1forERa-binding
and reverse BRCA1-mediated repression of ERa transcrip-
tional activity.
31,32 In our reporter assay, however,
the carboxy-terminus-truncated BRCA1 completely lost the
repression activity on the E2-induced IGF-1-EREL-Luc
transcription. These results suggest that the carboxy-terminal
repression domain of BRCA1 is further required to suppress
E2-dependent ERa transactivation of IGF-1 promoter. The
function of carboxy-terminal repression domain of BRCA1 is
not well understood yet, but BRCA1 interacts with several
factors through this domain. In fact, BRCA1 interacts with a
transcriptional repressor CtIP
33 and the histone deacetylase
complexincludingHDAC1andHDAC2
34throughthisdomain.
It has been also reported that association of BRCA1 with
HDAC2 epigenetically represses oncogenic microRNA-155
via deacetylation of histone H2A and H3 on its promoter.
35
In our data, BRCA1-KD itself induced IGF-1-EREL-Luc reporter
activity in the absence of E2 (Figure 3d). Taken together,
transcriptional corepressors may be recruited to ERa by
BRCA1.
Our data also indicate that transcription factors other than
ERa might regulate IGF-1 transcription in BRCA1-defective
cancers. First, BRCA1-KD-induced IGF-1 mRNA expression
is partially reduced by an estrogen antagonist ICI182780
in MCF7 cells under normal growth conditions, whereas
expression of IGF-1 mRNA is completely reduced
by ICI182780 in E2-stimulated BRCA1-KD MCF7 cells. This
result suggests that other transcription factors, which are
activated by serum-containing factors, may induce the
expression of IGF-1 mRNA in BRCA1-KD MCF7 cells.
Second, the carboxy-terminus of BRCA1 (BamHI (CT);
aa 1314–1863), lacking the ERa-interacting domain, still partially
represses E2-induced transcription of the wild-type IGF-1-
EREL-Luc reporter in MCF7 cells. It is possible that BRCA1
interacts with other transcription factors through its carboxy-
terminal repression domain in the regulation of the IGF-1
promoter. Third, the effects of tumor-associated BRCA1
mutants are different between the EREL site of IGF-1 and
consensus ERE. The BRCA1 T300G represses the IGF-1-
EREL-Luc reporter activity as strongly as wild-type BRCA1,
but did not suppress the consensus ERE-Luc activity.
20
These discrepancies also indicate that additional mechan-
isms including factors other than ERa may exist in the
regulation of the IGF-1 promoter. As reported, the EREL site
has sequence homology to both consensus ERE and AP1
sequences.
19 Interestingly, it has been reported that BRCA1
can interact with AP1 family proteins, Jun B and Jun D.
36
Thus, transcription factors, such as the AP1 family proteins,
may have important roles through these sequences. Further
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Cell Death and Diseasestudies are required to fully understand the exact molecular
mechanism by which BRCA1 regulates IGF-1 transcripts on
its promoter elements.
Recently,ithasbeenshownthattumor-suppressorfunction
of BRCA1 depends on BRCA C-terminus domain in mouse
model.
37 In our data, carboxy-terminal domain of BRCA1
is required to repress E2-dependent activation of IGF-1
promoter. Our data also suggest that dysregulation of IGF-1
expression by loss of BRCA1 function may induce a positive-
feedback loop, resulting further activation of IGF-1 transcripts
through the IGF-1R/PI3K/AKT pathway. Taken together, the
failure of several BRCA1 mutants in suppressing IGF-1
expression may be critical in the development, survival,
and/or proliferation of certain types of ER-positive breast
cancer.
Materials and Methods
Cell culture and reagents. All cell lines were purchased from American
Type Culture Collection (Manassas, VA, USA). MCF7 and DU145 were
maintained in Dulbecco’s Modiﬁed Eagle Medium (DMEM) containing 5% heat-
inactivated fetal bovine serum (HI-FBS; HyClone, Logan, UT, USA) and 100U/ml
penicillin/streptomycin. MCF10A was cultured in DMEM-F12 containing 5% horse
serum (Invitrogen, Carlsbad, CA, USA), 10mg/ml insulin, 10ng/ml epidermal
growth factor and 0.5mg/ml hydrocortisone. ZR-75-1 cells were maintained
in RPMI1640 containing 10% HI-FBS and 100U/ml penicillin/streptomycin.
Cell culture reagents were purchased from Invitrogen, Lonza (Basel, Switzerland),
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Cell Death and Diseaseor Cellgro (Manassas, VA, USA). The cell viability was evaluated via the trypan-blue
exclusion test using the Luna Cell Counter (Logos Biosystems, Gyunggi-Do, Korea).
For estrogen-deprivation conditions, MCF7 cells were maintained in phenol-red-free
DMEM (Invitrogen) containing 5% charcoal-stripped FBS (HyClone). Inhibitor
compounds were purchased from following sources: OSI-906 and BMS-754807
from MedKoo (Chapel Hill, NC, USA); AG 1024 from Enzo Life Science (Plymouth
Meeting, PA, USA); BMS-536924 and GSK1904529A from Selleck Chemicals
(Houston, TX, USA); and BEZ235 from LC Labs (Woburn, MA, USA). Stock
solutions of compounds were made with dimethyl sulfoxide (DMSO) (except for
BEZ235 in dimethylformamide and Perifosine in H2O) and stored at  201Ci n
small aliquots. Estradiol (Sigma, St. Louis, MO, USA) and ICI182780 (Tocris
Bioscience, Minneapolis, MN, USA) were dissolved in ethanol.
siRNA transfection. The cells were pretreated with 100nM siRNA for 72h,
reseeded into either six-well plates for western blot and ELISA or 96-well plates for
MTT assay, and then further transfected with 100nM of fresh siRNA using
Lipofectamine 2000 (Invitrogen). For MTT assay, the day after transfection, media
containing inhibitors were added to each well in triplicate. The siRNAs were
obtained from Dharmacon (Lafayette, CO, USA): control-siRNA, 50-GACGAGCG
GCACGUGCACAUU-30; BRCA1 siRNA, 50-GAAGCCAGCUCAAGCAAUAUU-30;
and BRCA1 siRNA, 50-GAAGGAGCUUUCAUCAUUCUU-30.
MTT assays. Cell proliferation was assayed at 48–72h after treatment of
compounds by adding 20ml of 5mg/ml MTT solution per 100ml of growth medium.
After incubation for 2–4h at 371C, the media were removed and MTT solvent
(4mM HCl, 0.1% Nonidet-40 in isopropanol or absolute DMSO) was added to
dissolve the formazan. The absorbance of each well was measured by ELx808
Microplate Reader (BioTek, Winooski, VT, USA). Viable cells were calculated as a
percent of the control.
Construction of IGF-1 promoter and reporter gene assay. Human
IGF-1 promoter reporter (IGF-1-1kb-Luc) containing B1kb of the upstream region
of human IGF-1 gene was purchased from SwitchGear Genomics (Menlo Park,
CA, USA). PCR reactions were performed to amplify the EREL sequence on the
IGF-1 promoter. The following sequences of primers were used: pGL3, 50-ACCA
ACAGTACCGGAATGCC-30; wild-type IGF-1 EREL, 50-ACTCAATAACTTTGCCAG
AAGAGGTTACGCGTGCTAGCCCGGGC-30; mutant IGF-1 EREL, 50-ACTC
AATAACTTGAAGAGGTTACGCGTGCTAGCCCGGGC-30. PCR products were
subcloned into the pCR2.1-TOPO vector (Invitrogen) and EREL-containing
regions were digested using SacI and HindIII restriction enzymes and ligated
into the pGL3-control vector. MCF7 cells in 24-well plates were transfected with
125ng/well of the reporter DNA, 50ng/well of the b-galactosidase expression
vector, and increasing amounts of BRCA1 expression vector by Lipofectamine
Plus (Invitrogen). Luciferase activities from cell lysates were measured by the
Victor2 plate reader (PerkinElmer, Waltham, MA, USA) at the Genomics and
Epigenomics Shared Resource at Georgetown University Medical Center and
normalized to b-galactosidase activities.
DNA transfection. Expression vectors for wild-type or mutant BRCA1 protein
are described previously.
38,39 DNA transfection was performed using Lipofecta-
mine Plus (Invitrogen) as described previously.
39 After 24h of transfection, cells
were plated into either 24- or 48-well plates with normal growth medium. The day
after plating, cells were treated with normal growth media containing inhibitors for
48–72h. All experiments were performed in triplicate and MTT assay was used to
measure the viability of cells.
qRT-PCR. qRT-PCR was performed in triplicate with the Fast SYBR green
master mix (Applied Biosystems, Carlsbad, CA, USA) using an Applied
Biosystems-Prism Sequence Detector System 7700 at the Genomics and
Epigenomics Shared Resource, Georgetown University Medical Center, and
analyzed with SDS software. The following primer sequences were used: BRCA1
(forward) 50-CAGCGATACTTTCCCAGAGC-30, (reverse) 50-GTCCCTTGGGGTTT
TGAAAT-30; IGF-1 (forward) 50-GCTCTTCAGTTCGTGTGTGG-30, (reverse) 50-CC
TGCACTCCCTCTACTTGC-30; IGF-2 (forward) 50-ACACCCTCCAGTTCGTCTG
T-30, (reverse) 50-GGACTGCTTCCAGGTGTCAT-30; IGF-1R (forward) 50-CCAAA
ACTGAAGCCGAGAAG-30, (reverse) 50-ATCGATGCGGTACAATGTGA-30; IRS-1
(forward) 50-AAGCACCTGGTGGCTCTCTA-30, (reverse) 50-AGAGTCTCCACCTG
CATCC-30; and GAPDH (forward) 50-GTATGACAACGAATTTGGCTACAG-30,
(reverse) 50-AGCACAGGGTACTTTATTGATGGT-30.
Chromatin immunoprecipitation (ChIP). ChIP assays were performed
using the ChIP-IT assay kit (ActiveMotif, Carlsbad, CA, USA). The sheared
chromatin was immunoprecipitated with an ER-a antibody (HC-20; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), BRCA1 antibody (Ab1þAb4; Calbiochem,
Gibbstown, NJ, USA), or normal IgG. The following primers were used: IGF-1
promoter ( 111 to  312) (forward) 50-TTGTCACCATGCCCAAAAAA-30,
8
(reverse) 50-TTGCGCAGGCTCTATCTGC-30 and IGF-1 non-ERE promoter region
( 956 to  797) (forward) 50-CAGGTTTGAGTTATATGG-30, (reverse) 50-TGCC
GAGCTCTAAAACCC-30.
Neutralizing IGF-1 antibody and IGF-1 ELISA. Human IGF-1
neutralizing antibody (AF-291-NA) was purchased from R&D Systems (Minnea-
polis, MN, USA). For neutralizing IGF-1, siRNA-transfected cells were further
treated with 2 or 5mg of IGF-1 neutralizing antibody for an additional 24h. Media
(50ml) from siRNA-transfected cells were tested for IGF-1 concentrations
using the human IGF-1 Quantikine ELISA kit (R&D Systems) according to the
manufacturer’s protocol.
Western blots and antibodies. Western blot analyses were performed
using cleared cell lysates as described previously.
40 Antibodies used in this study
were as follows: BRCA1 (C-20) (sc-642) from Santa Cruz Biotechnology;
phospho-GSK3b (Ser9) (# 9323), GSK3b (# 9332), phospho-Akt (Ser473)
(# 9271), Akt (# 9272), phospho-IGF-1Rb (Y1135) (# 3918) and IGF-1Rb (# 3027)
from Cell Signaling (Danvers, MA, USA); and b-actin (A1978) and horseradish
peroxidase-conjugated secondary antibodies from Sigma.
Statistical methods. The two-tailed Student’s t-test was applied for
statistical analysis. * indicates Po0.05; ** indicates Po0.01; and *** indicates
Po0.001. For the bar graphs, *, **, and *** evaluated the statistical signiﬁcance of
comparisons with the controls of interest.
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